Fax: (011) 81-0422-79-3471
Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas
Tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component
Article first published online: 19 JAN 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 4, pages 741–750, 15 February 2007
How to Cite
Ohtsuka, K., Ohnishi, H., Fujiwara, M., Kishino, T., Matsushima, S., Furuyashiki, G., Takei, H., Koshiishi, Y., Goya, T. and Watanabe, T. (2007), Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas. Cancer, 109: 741–750. doi: 10.1002/cncr.22476
- Issue published online: 2 FEB 2007
- Article first published online: 19 JAN 2007
- Manuscript Accepted: 27 NOV 2006
- Manuscript Revised: 22 NOV 2006
- Manuscript Received: 23 AUG 2006
- lung cancer;
- nonsmall-cell lung cancer (NSCLC);
- squamous-cell carcinoma;
- adenosquamous carcinoma;
- large-cell carcinoma;
- epidermal growth factor receptor (EGFR);
Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma. However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma. The present study sought to gain further insight into the significance of EGFR mutations in NSCLC by focusing on nonadenocarcinoma NSCLC.
EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas. In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines. EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element. Patients with such lesions are thus considered candidates for molecular therapies targeting EGFR. Cancer 2007 © 2007 American Cancer Society.